Suggested remit: To appraise the clinical and cost effectiveness of selpercatinib within its marketing authorisation for treating RET fusion-positive advanced non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 3743

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
14 May 2020 - 12 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance